Navigation Links
EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer

HUNTSVILLE, Ala., June 3 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Khursheed Anwer, Ph.D., has been promoted to President and Chief Scientific Officer. He will succeed Danny H. Lewis, Ph.D., who has retired from the position of President and Chief Executive Officer. Dr. Lewis will continue to support the company on scientific and business affairs and retain his position on EGEN's Board of Directors.

"The Board would like to thank Dr. Lewis for his invaluable contributions over the past five years. Under Dr. Lewis' leadership EGEN has developed a proprietary technology platform, moved a novel cancer product through two human clinical trials, developed a family of RNAi delivery technologies and put the Company on solid financial footing. We are delighted that he will continue his contributions as a member of EGEN's Board of Directors," said Milton Harris, Ph.D., Chairman of EGEN. "At the same time, we are excited to have Dr. Anwer assume the role of President. He has demonstrated impressive strategic and leadership skills, advancing EGEN's science from the bench to the clinic. We are pleased to have him lead the continued development of EGEN's novel technology for RNAi delivery and clinical development of its oncology product."

"This is an excellent time to transition EGEN's leadership," said Dr. Lewis. "EGEN is in good shape on all fronts, but especially with the team of people EGEN has in all roles. It has been a pleasure to be part of this group. We are fortunate to have a scientific leader like Dr. Anwer available to take the helm."

Dr. Anwer possesses more than 15 years of management and scientific leadership experience in the biotechnology industry and has authored more than 40 publications during his active career in research and development. He has served EGEN in a variety of scientific leadership positions since 2002, most recently as Senior Vice-President and Chief Scientific Officer. In these positions he has led the execution of EGEN's proprietary discovery and development initiatives leading to EGEN's strong intellectual property position, was instrumental in building EGEN's research and development team and fostered important industry collaborations that are underway.

"I am pleased to have the opportunity to continue my personal contributions to EGEN's success," said Dr. Anwer. "I look forward to working with the Board of Directors and moving EGEN's technology forward to create additional value for our shareholders. We are poised to take the company's novel technology to the next level and make the promise of nucleic acid (DNA, RNAi) therapeutics become a reality."

About EGEN, Inc.

EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

For more information on EGEN, please visit .

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
2. Amylin Announces Preliminary Tabulation of Annual Meeting Results
3. Cynosure Announces Presentations at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
5. Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins
6. Valeritas Announces Appointment of New CEO
7. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... --> Paris from 17 th ... the biometrics innovation leader, has invented the first combined scanner ... the same scanning surface. Until now two different scanners were ... scanner can capture both on the same surface. This ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):